Psoriasis clearance more than twice as likely with zasocitinib vs deucravacitinib
Takeda's zasocitinib showed superior efficacy over Bristol Myers Squibb's deucravacitinib in treating moderate to severe plaque psoriasis, with 36.5% of participants achieving complete clearance vs. 13.9%, according to a phase 3 study presented at the European Academy of Dermatology and Venerology Congress. Zasocitinib also demonstrated faster and more complete effects, with no new safety signals observed.
How this was made
The 30-second read
Why it matters
Zasocitinib shows higher complete clearance and better secondary endpoints at week 16 with no new safety signals, which can shift competitive expectations for TYK2 inhibitors in dermatology.
Market read
Traders may reprice near-term biotech sentiment based on statistically significant head-to-head efficacy superiority and the absence of new safety concerns.
What to watch
The article does not provide subgroup results, prior treatment status, or long-term safety; also, it does not clarify whether dosing schedules or patient characteristics could influence comparative response rates.
Background
The article reports late-breaking Phase 3 head-to-head results (LATITUDE Atlas) comparing investigational zasocitinib (Takeda) versus deucravacitinib (Sotyktu, Bristol Myers Squibb) in moderate-to-severe plaque psoriasis.
Ticker impact
Late-breaking LATITUDE Atlas Phase 3 data show 36.5% complete clearance at week 16 with zasocitinib versus 13.9% for the comparator, with no new safety signals.
Likely upward bias as traders price in stronger clinical differentiation versus Sotyktu, offset by remaining uncertainty around approval and durability.
The article reports statistically significant superiority on multiple PASI/PGA endpoints and states no new safety signals, which is typically supportive for biotech sentiment, but it is still investigational and conference-only.
Deucravacitinib (Sotyktu) in the LATITUDE Atlas head-to-head trial underperformed zasocitinib on PASI 100 at week 16 (13.9% vs 36.5%).
Likely downward or defensive bias as the market reassesses competitive strength, though the impact may be limited if Sotyktu’s approved-label performance remains unchanged.
The study is head-to-head and shows clear statistical superiority for the investigational drug, but the article does not indicate any new safety issue for deucravacitinib or changes to its approved status.
Market effects
Reinforces competitive intensity in TYK2 inhibitor space, with head-to-head efficacy differentiation becoming a key narrative driver for dermatology pipelines.
Primarily impacts US-listed large-cap biotech sentiment (Takeda via ADR, Bristol Myers) rather than broad regional flows.
Conference read-through can influence global biotech risk appetite for dermatology and TYK2 programs.
Counterpoint
Head-to-head conference data may not translate into label-level outcomes or payer adoption; traders may overreact to PASI/PGA endpoint differences without knowing long-term durability and real-world tolerability.
Key entities
- clinical_trialLATITUDE Atlas
Phase 3 head-to-head study comparing zasocitinib vs deucravacitinib in plaque psoriasis, primary endpoint PASI 100 at week 16.
- drugzasocitinib
Investigational highly selective oral TYK2 inhibitor associated with Takeda in the article.
- drugdeucravacitinib (Sotyktu)
TYK2 inhibitor associated with Bristol Myers Squibb in the article.
- conferenceEuropean Academy of Dermatology and Venerology Congress
Venue where the late-breaking data were presented.
